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1. Introduction 
Diabetes insipidus in pregnancy (diabetes insipidus gravidarum, gestational diabetes insipidus 
or pregnancy-related diabetes insipidus) is considered to be a rare disease complicating up 
to 1 in 25000-30000 pregnancies; however, emerging evidence suggests that often the disease 
is under-diagnosed (Aleksandrov et al., 2010). As stated by the Italian E. Momigliano, in 
1929, in his first monograph on 31 cases of pregnancy-related diabetes insipidus 
(Momigliano, 1929), the disease may occur in an apparently healthy woman, during any 
stage of pregnancy, usually in the latter half, or may aggravate during pregnancy when 
previously diagnosed. As a paradox, the disorder may disappear days to weeks after 
delivery, or may alleviate, or remain unaltered (Bleakley, 1938). Moreover, aggravated 
recurrence of the disorder in successive pregnancies is recognized (Blotner & Kunkel, 1942).      
Interest towards pregnancy-related diabetes insipidus revived about 20-30 years ago, once it 
became apparent that this clinical condition is closely associated with liver disease, HELLP 
syndrome and the wide spectrum of preeclampsia, all with potentially serious consequences 
on the maternal course of gestation and fetal health and development.  
The aim of the present book chapter is to review the body water homeostasis during 
pregnancy as well as to insist on clinical conditions associated with the occurrence of 
diabetes insipidus in pregnancy and the early postpartum period. Not only true gestational 
diabetes insipidus will be addressed but, notably, maternal hypothalamic-pituitary diseases 
associated with diabetes insipidus presenting high incidence during pregnancy and the 
postpartum period will be detailed. It is the author’s hope that at the end of the chapter, the 
reader will find answers to hot questions on the intimate mechanisms facilitating gestational 
diabetes insipidus, the need to screen or not for alterations in water metabolism in pregnant 
women at risk, the challenges in differential diagnosis of arginin-vasopressin (AVP) 
disturbances in a pregnant women and the associated clinical conditions including 
preeclampsia, acute fatty liver and HELLP (Hemolysis-Elevated Liver enzymes-Low Platelets) 
syndrome.  
In addition, etiological considerations on AVP deficiency or defective hormone action in the 
fetus and neonate will be made.  
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2. General adaptations of the endocrine system and the maternal 
hypothalamic-pituitary axis to pregnancy  
The fetal-placental unit develops as a unique endocrine organ in pregnancy to account for 
various endocrine changes. It synthesizes large amounts of hormones; in turn, these 
synthesis products are secreted into the fetal and maternal circulation. After 8 weeks of 
gestation, the placenta is the main source of progesterone, which derives from maternal 
LDL-cholesterol. Most of placental progesterone enters the maternal circulation and hence 
maternal progesterone plasma concentrations gradually raise during pregnancy up to 150 
ng/ml. Likewise, 17ß-estradiol and estrone are produced by the placenta via conversion 
from both maternal and fetal DHEA-S, whereas estriol is formed in the placenta from fetal 
adrenal DHEA-S as the primary source. In both mother and child, serum human chorionic 
gonadotropin (hCG) levels increase progressively to reach a peak at 10-14 weeks of 
pregnancy and thereafter fall until delivery. Undoubtedly, hCG is involved in 
steroidogenesis and maintenance of the corpus luteum activity during the first weeks of 
gestation. Unlike hCG, the plasma levels of human placental lactogen hormone (hPL) 
increase throughout the pregnancy to plateau at term. Human PL is secreted mostly into 
maternal circulation to induce lipolysis, resulting in increased availability of free fatty acids; 
it inhibits glucose uptake and gluconeogenesis in the mother, all these metabolic effects 
predisposing to maternal insulin resistance and hyperinsulinemia. Recently, human 
placental growth hormone (hPGH) synthesis was certified in pregnant women; it gradually 
replaces pituitary GH during pregnancy and is supposed to promote placental and fetal 
growth (Chellakooty et al., 2002).  
In order to adapt to fetal requirements, pregnancy per se is associated with considerable 
changes in the maternal endocrine status, including physiological changes of the 
osmoregulatory system. Some of the most significant changes occur in the anterior pituitary 
and thyroid glands to meet the nutritional needs of the fetus. The pituitary gland enlarges 
during normal gestation due to estrogen- and to a lesser extent progesterone-induced 
hyperplasia of lactotroph cells, explaining 10-fold increased maternal prolactin (PRL) levels 
by the end of pregnancy. By the 6th to 7th week of pregnancy, basal and stimulated GH 
release from the maternal pituitary is suppressed via placental GH-induced IGF-1 synthesis 
(Chellakooty et al., 2002). By the same time, follicle-stimulating (FSH) and luteinizing 
hormone (LH) levels start to decrease along to their response to gonadotropin-releasing 
hormone (GnRH) stimulation.  
Iodine requirements are increased in the pregnant woman up to 200-300 µg daily due to 
accelerated renal clearance and transplacental passage of inorganic iodine to supply fetal 
needs. Additional mechanisms consist of increased thyroid hormones demands to 
compensate for high thyroxin binding globulin (TBG) levels in the mother, stimulation of 
the thyroid gland by the thyrotropin-like activity of hCG, and activity of the type 3 placental 
deiodinase (Glinoer, 1997).  
The hypothalamic-pituitary-adrenal axis is subjected to significant changes during 
pregnancy as evidenced by increased maternal cortisol levels, mainly because of an increase 
in the concentration of corticosteroid binding globulin (CBG), and reduced cortisol 
clearance. But it is also observed that free cortisol levels are higher during the second 
trimester and plateau in the third. Several mechanisms are thought to be involved: an 
altered set point for ACTH, effects of placental ACTH on adrenal hormone production, 
antiglucocorticoid actions of progesterone, and cortisol resistance (Karaca et al., 2010). 
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Notably, the placental 11ß-hydroxysteroiddehydrogenase efficiently protects the fetus from 
maternal hypercortisolism by cortisol inactivation. In addition, placental synthesis of CRH is 
demonstrated. Placental CRH is under the control of cortisol by positive feed-forward and 
behaves as a determinant of onset of parturition (Kalantaridou et al., 2003). 
Both estrogen and progesterone activate synthesis of renin and, subsequently, production of 
angiotensin II and aldosterone, respectively. Nevertheless, the maternal vasculature 
becomes refractory to the pressor effects of angiotensin II, a phenomenon essential to blood 
volume expansion during pregnancy. Moreover, the physiological action of aldosterone is 
counteracted by progesterone, a competitive inhibitor of aldosterone in the distal tubule. 
3. Water balance, arginin-vasopressin metabolism, aquaporin-2 expression 
and vasopressinase activity in pregnancy 
3.1 Hemodynamic changes and water metabolism in normal pregnancy 
Pregnancy is a physiological condition associated with water retention which is especially 
prominent in the last trimester. Studies of body fluid volume regulation in normal human 
pregnancy pointed out towards water retention leading subsequently to increased total 
blood volume and decreased plasma osmolality. In both humans and rats, a 30–50% increase 
in extracellular fluid, plasma and blood volume was reported (Schrier & Briner, 1991). At 6 
weeks of pregnancy, an early decrease in systemic and renal vascular resistance with under-
filling of the arterial system is documented. As compensatory mechanisms, this will induce 
sympathetic system stimulation and enhanced cardiac output as well as activation of the 
renin-angiotensin-aldosterone (RAA) system with associated renal sodium and water 
retention, leading to the abovementioned expansion of total plasma volume. Evidence of 
arterial vasodilatation as a primary event of the hyper-dynamic circulatory status in 
pregnancy is offered by animal studies, such as the rat. Indeed, this appears to be a 
hormone-triggered mechanism, since up-regulation of endothelial nitric oxide synthase 
(eNOS) by estradiol has been documented. In line with this finding, increased expression of 
the eNOS gene in the aorta wall, and elevated plasma nitrite and nitrate levels were detected 
in pregnant rats. Moreover, neural NOS expression was also found to be increased in the 
hypothalamus of pregnant rats. In turn, inhibition of the NOS activity has been shown to 
result in a reverse of renal and systemic vascular changes and normalization of cardiac 
output (Schrier & Ohara, 2010). 
Pregnancy-mediated vasodilatation itself results in non-osmotic AVP release from the 
hypothalamus. During pregnancy, the osmotic threshold at which pregnant women 
manifest thirst and release AVP is shifted to a level lower to that of non-pregnant women 
(Lindheimer & Davison, 1995). Subsequently, a decrease of about 10 mOsm/kg in plasma 
osmolality ensues starting with the 6th week of pregnancy. Similar changes may be induced 
in non-pregnant women in whom exogenous hCG is administered (Davison et al., 1988).  
Thus, reduction in arterial pressure of more than 10-20% releases AVP from the posterior 
pituitary by lowering the osmoregulatory system set point, an effect mediated by 
stimulation of baroreceptors located in the walls of the left atrium and large arteries and 
leading via the glossopharyngeal and vagal nerve to the CNS and then the hypothalamus. 
Nevertheless, non-osmotic AVP release is not unique during physiological pregnancy but 
also occurs in adrenal insufficiency, pathological low-output congestive cardiac failure or 
liver cirrhosis, in the last triggered by splanchnic arterial vasodilatation. Likewise, orally 
active non-peptide-selective V2 receptor antagonists administered to patients with cardiac 
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failure or cirrhosis of the liver increase urinary water excretion while reversing 
hyponatremia (Schrier et al., 1998). Eventually, the non-osmotic AVP stimulation during 
pregnancy will promote water retention and increased body fluid volume with plasma 
hypoosmolality. Figure 1 presents hemodynamic changes and adaptations of water and 
AVP metabolism during normal pregnancy.  
 
 
Fig. 1. Hemodynamic changes and adaptations of water and AVP metabolism in normal 
pregnancy. 
3.2 Aquaporin-2 and vasopressinase activity in normal pregnancy 
Water molecules transport across membranes is mediated by water channel proteins called 
aquaporins. Of the several isoforms of aquaporins identified in the kidney and other organs 
(brain, liver, pancreas, colon, spleen, lung, submandibular gland, testes, leukocytes), 
aquaporin-2 is abundant in the collecting duct principal cells and is the main target for AVP 
effects to mediate water transport across the apical membrane of the renal collecting duct. In 
response to AVP, aquaporin-2 is translocated from cytoplasmic vesicles to apical plasma 
membranes by shuttle trafficking to increase water permeability of the membrane. After 
ending AVP stimulation, aquaporin-2 is redistributed and stored into cytoplasmic vesicles.  
Excretion of aquaporin-2 in the urine can be quantified and it appears that urinary 
aquaporin-2 may reflect the levels and/or activity of aquaporin-2 in the apical plasma 
membrane of the collecting duct. Analysis of urinary aquaporin-2 concentrations shows 
acute or long-term changes of the protein in a number of clinical conditions associated with 
water balance disorders. In that sense, low aquaporin-2 expression has been described in 
forms of nephrogenic diabetes insipidus (e.g. hypokalemia, hypercalcemia, lithium therapy, 
post-obstructive polyuria) as a mechanism for the inability of the kidney to concentrate 
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urine in these conditions. In the pregnant rat, up-regulation of aquaporin-2 expression and 
aquaporin-2 trafficking was described. Administration of the V2 receptor antagonist in 
pregnant rats suppressed the increase in aquaporin-2 mRNA and aquaporin-2 protein levels 
despite normal levels of plasma vasopressin thus suggesting that in pregnancy the up-
regulation of aquaporin-2 contributes to water retention in part through a V2 receptor-
mediated effect. In addition, vasopressin-independent factors (such as oxytocin) may be 
important for this up-regulation. 
Likewise, in pregnant women, up-regulation of aquaporin-2 expression and enhanced 
urinary protein levels have been substantially documented (Frokier et al., 1998); 
accordingly, this effect on aquaporin-2 is reversed by a V2 receptor antagonist (Schrier, 
2010). In a study of healthy pregnant primiparas, urinary aquaporin-2 excretion, plasma 
oxytocin and atrial natriuretic peptide but not plasma AVP levels were significantly higher 
in all three trimesters of pregnancy compared to age-matched non-pregnant women (Buemi, 
2001) thus suggesting possible effects of an AVP-independent factor to stimulate renal 
aquaporin-2 expression during pregnancy. 
In healthy adults, AVP circulates in an unbound state and equilibrates within minutes 
between plasma and the extracellular fluid. Its concentration in these compartments 
decreases with an average half-time of approximately 20 minutes. Normally, AVP is 
clearanced by the kidney or degraded by the liver; only a small quantity of AVP is taken up 
and stored by the platelets. During pregnancy, the increased AVP secretion is countered by 
a 3-fold to 6-fold increase in the metabolic clearance rate of vasopressin which is due to an 
enzyme, the vasopressinase. Vasopressinase is a plasmatic leucyl-cystinyl-aminopeptidase 
that degrades both AVP and oxytocin produced by the syncytiotrophoblast of the placenta. 
Because the placental trophoblastic mass increases about 1000-fold from 6 to 24 weeks of 
gestation, plasma vasopressinase levels may be 20-fold higher by the third trimester of 
pregnancy (Soule et al., 1995). Aside to vasopressinase, another enzyme of placental origin, 
leucine-aminopeptidase (oxytocinase) appears to contribute to AVP degradation during 
pregnancy. Plasma concentrations of leucine-aminopeptidase gradually increase during 
pregnancy until delivery, acting as an anti-uterotonic agent by degrading uterotonic 
peptides. Recently, preeclampsia was associated to low leucine-aminopeptidase levels 
(Landau et al., 2010). The accelerated AVP degradation resolves about 40 days post-delivery. 
Despite the increase in the clearance of AVP due to vasopressinase activity, in normal 
pregnancies, AVP levels remain unchanged thus suggesting a compensatory increase in 
synthesis and release. Nevertheless, it has to be pointed out that these adaptations are of no 
particular clinical relevance unless a pathological process is present.  
Genetically AVP-deficient homozygous Brattleboro (BB) rats suffer from severe diabetes 
insipidus. The pregnant BB rat may serve as an animal model of central diabetes insipidus 
associated to pregnancy. Early studies have shown that the osmotic threshold for AVP 
during pregnancy is lower in both BB rats and controls and that, in the homozygous animal, 
chronic vasopressin treatment increased urine osmolality less compared with virgins 
(Barron et al., 1985). Nevertheless, the model does not apply to true gestational diabetes 
insipidus since this is induced by enhanced vasopressinase activity and metabolic AVP 
clearance. Besides AVP, oxytocin and relaxin may play a role in controlling water balance 
during physiological pregnancy. BB rats were found to significantly concentrate their urine 
upon severe dehydration, and the plasma level of oxytocin was found to be about 6-fold 
higher under these circumstances (Edwards & LaRochelle, 1984). An antidiuretic effect of 
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oxytocin was evidenced in both normal individuals and central diabetes insipidus. Oxytocin 
has an affinity for the V2 receptor two orders magnitude lower compared to that of l-
desamino-8-D-arginine (DDAVP). However, in a small study of healthy and diabetic men, 
oxytocin infusion resulted in decreased urine outflow and free water clearance and 
increased urine osmolality and aquaporin-2 urinary excretion (Koo et al., 2003) thus 
suggesting that, in man, the antidiuretic effect of oxytocin may be mediated by regulation of 
aquaporin-2 levels in the collecting duct.  
Relaxin is characterized as a pregnancy-related hormone secreted by the corpus luteum 
involved as a key player in maternal systemic and renal vasodilatation during pregnancy, as 
revealed by the vasodilatation obtained in non-pregnant rats in response to intravenous 
relaxin administration. In human, emerging evidence suggests that the effect of relaxin is 
mediated by the relaxin/insulin-like family peptide 1 receptor, RFXP1, through a Gα-
protein coupled to phosphatidylinositol-3kinase/Akt (protein kinase B)-dependent 
phosphorylation and activation of endothelial nitric oxide synthase to induce nitric oxide 
synthesis and, hence, important vasodilatation (Conrad, 2011).  
4. Etiology and clinical presentation of pregnancy-related diabetes insipidus 
4.1 Etiology of polyuria in pregnancy 
Table 1 depicts potential causes of polyuria in pregnant women. 
 
Solute Diuresis Water Diuresis 
Diabetes mellitus Primary polyuria 
Salt-losing tubulopathy Diabetes insipidus 
Saline loading Hyperkalemia 
Post-obstructive diuresis Hypercalcemia 
Osmotic iatrogenic diuresis  Primary or secondary tubulopathies 
 Sickle cell anemia 
Table 1. Causes of polyuria in pregnancy (adapted after Barbey et al., 2010). 
Etiologic characterization of diabetes insipidus during pregnancy is complex and, in some 
cases, difficult to ascertain to one or the other related clinical conditions. Should diabetes 
predate pregnancy, in either overt or sub-clinical form, any disorder causing AVP-
deficiency or AVP-resistance has to be taken into account. On the other hand, pregnancy 
itself may prone to development of pathological conditions of inadequate AVP synthesis or 
action, usually in a transient form during pregnancy and postpartum, but, occasionally, 
persisting thereafter. In synthesis, diabetes insipidus during pregnancy may reveal itself as: 
• Pre-gestational diabetes insipidus, either central (AVP-deficient) or nephrogenic (AVP-
resistant)  
• Latent (sub-clinical) central or nephrogenic diabetes insipidus, unmasked by both increased 
vasopressinase activity and diminished renal responsiveness to vasopressin (Iwasaki et 
al., 1991) 
• True gestational diabetes insipidus, as  
• Transient gestational diabetes insipidus which manifests in pregnancy and usually 
resolves 3-6 weeks after delivery. Multiple pregnancy acts as a risk factor. Transient 
gestational diabetes insipidus may be associated with preeclampsia, acute fatty 
liver disease or HELLP syndrome, or unmask prevalent liver disease such as in 
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hemochromatosis (Krysiak et al., 2010). As abovementioned, an underlying sub-
clinical deficiency in AVP may also be involved in some, if not all, patients.  
• Recurrent diabetes insipidus of pregnancy due to increased vasopressinase activity has 
been reported in subsequent pregnancies in several women. Both transient and 
recurrent gestational diabetes insipidus are vasopressin-resistant but respond well 
to desmopressin (DDAVP). 
• Transient, vasopressin- and DDAVP-resistant gestational diabetes insipidus which is a 
consequence of the physiological increase in the concentration of prostaglandin E2 
in the kidney during gestation leading to inhibition of AVP action at the level of its 
receptor (Jin-No et al., 1998) 
• Postpartum diabetes insipidus (i.e. lymphocytic hypophysitis, pituitary apoplexy, 
histiocytosis X, pituitary tumor, Sheehan’s syndrome). Even though these pathological 
conditions clearly predominate within the first year after birth (postpartum period), 
concomitance with pregnancy is not excluded in any of them, except for Sheehan’s 
syndrome. 
In rare cases, gestational diabetes insipidus may develop as nephrogenic form manifested in 
pregnancy and complicated by preeclampsia (Goodman et al., 1984; Korbet et al., 1985). 
Diabetes insipidus may persist postpartum or may be a transient latent form of the disease. 
4.2 Clinical features of pregnancy-related diabetes insipidus, and associated 
conditions 
Clinical presentation of pregnancy-related diabetes insipidus is usually acute with 
symptoms developing in a few days. An abrupt change in the voiding pattern during the 
last trimester of pregnancy manifesting as hypotonic polyuria, and excessive water intake 
represent the hallmark of the disease. Fatigue, nausea, weight loss, and reduced skin turgor 
may be seen. Women in whom diabetes insipidus is associated to a more complex morbid 
status may present additional symptoms and clinical signs.  
4.2.1 Pregnancy-related liver disease 
Pregnancy-related liver disease comprises a large spectrum of liver disturbances specifically 
to pregnancy, with variable outcome potential. While liver dysfunction is transient and 
usually mild in hyperemesis gravidarum and intra-hepatic cholestasis of pregnancy, women 
with acute fatty liver disease or HELLP syndrome are at high risk to concomitantly develop 
preeclampsia and a less favorable prognosis. Differential diagnosis between pregnancy-
related liver disease and preexistent or simultaneous hepatic disorder unrelated to 
pregnancy is mandatory and sometimes difficult.  
Nevertheless, rarely, liver biopsy is employed as an ultimate differential diagnosis tool. 
Association of de novo diabetes insipidus with liver injury in pregnant women is suggested 
by polyuria and polydipsia syndrome and epigastric pain, nausea, vomiting, pruritus and 
jaundice. At least in some patients, acute fatty liver disease can be considered as an atypical 
form of preeclampsia because 30-40% of women with acute fatty liver also develop 
preeclampsia. In that sense, onset of diabetes insipidus in patients with acute fatty liver may 
highly indicate the likelihood of preeclampsia. Hence, early delivery and supportive care 
may considerably improve the overall prognosis of these individuals. Pathogenesis of 
diabetes insipidus in pregnant women with acute fatty liver can be easily explained by 
enhanced vasopressinase activity subsequent to liver dysfunction. Commonly, diabetes 
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insipidus responds well to DDAVP therapy and spontaneously resolves with delivery or 
may persist postpartum for another few weeks.  
Recently, it has been found that acute fatty liver of pregnancy is associated with a defect of 
long-chain 3-hydroxyacyl coenzyme A dehydrogenase in the fetus with c1528G>C point 
mutation as the main cause (Guttiérez Junquera et al., 2009). Therefore, genetic testing can 
be taken into consideration in both the mother and the fetus.  
Association of advanced hepatocytolysis, hemolysis and thrombocytopenia gives birth to 
the HELLP syndrome, one component of systemic preeclampsia and eclampsia, often 
conjoined with diabetes insipidus, hypertension and cerebral edema. HELLP syndrome 
occurs in 10-20% of pregnancies with severe preeclampsia. The majority of cases (70%) 
develop in advanced pregnancy, between the 27th and 37th gestational week, and seldom 
later; the reminder within 48 hours after delivery, usually in women who developed 
proteinuria, hypertension, edema and excessive weight gain prior to delivery. 
Recent studies hypothesized genetic predisposition as a risk factor for HELLP syndrome, 
mainly under the form of various disturbances in the process of blood coagulation. 
Therefore, some clinical studies investigated the association between hereditary 
thrombophilia and HELLP syndrome but results remain controversial (Ganzevoort et al., 
2007; Larciprete et al., 2010). Several reports confirmed statistically higher incidence of 
antithrombin-III deficiency in patients with HELLP syndrome (Larciprete et al., 2010; Dogan 
et al., 2011). Apparently, women with elevated antiphospholipid antibodies titers are at risk 
to develop severe preeclampsia and HELLP syndrome (Heilmann et al., 2011).  
Onset of HELLP syndrome is within days or weeks with headache, visual symptoms, 
malaise, nausea and vomiting and fluctuating abdominal pain. Most symptoms exacerbate 
during night. Para-clinical investigations will exhibit proteinuria, low hemoglobin levels 
and increased serum lactate dehydrogenase (LDH) concentrations to attest for onset of 
microangiopathic hemolytic anemia (Haram et al., 2009) in these patients. Elevated levels of 
liver enzymes (ASAT, ALAT and α-glutathione-S-transferase-a1) are documented. 
Thrombocytopenia is the result of subsequent increased platelet consumption and, thus, 
platelet turnover. If diabetes insipidus is present, hypernatremia, hemoconcentration and 
diminished urine/plasma osmolality ratio is expected. Table 2 summarizes the diagnosis 
criterions of HELLP syndrome according to the two major current definition systems.  
 
HELLP Syndrome 
Mississippi Classification 
Criteria 
Tennessee Classification 
Criteria 
Platelet count ≤50 x 109/L 
AST or ALT ≥70 IU/L 
LDH ≥600 IU/L 
Platelet count ≤100 x 109/L 
AST ≥70 IU/L 
LDH ≥600 IU/L 
Table 2. Current diagnosis criteria for the HELLP syndrome. 
Based on the platelet count, the Mississippi system categorizes the disorder into class 1 
HELLP (table 2) and class 2 HELLP syndromes (i.e. platelet count ≤100 x 109/L and >50 x 
109/L, serum liver enzymes ≥70 IU/L and serum LDH ≥600 IU/L). In addition, class 3 
HELLP syndrome is defined according to Mississippi classification as platelet count ≤150 x 
109/L and >100 x 109/L, serum liver enzymes ≥40 IU/L and serum LDH concentration ≥600 
IU/L (Martin et al., 1999). Class 3 HELLP syndrome is considered a transitional group.  
The clinical significance of HELLP syndrome is based upon severe maternal and 
fetal/neonatal complications that may occur in affected pregnancies. Biochemical 
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abnormalities associated with increased risk of maternal complications consist of serum 
LDH levels >1400 IU/L, serum AST >150 IU/L, serum ALT >100 IU/L and serum uric acid 
levels >7.8 mg% (Magann & Martin, 1999). In the mother, life-threatening complications are 
abruptio placentae, disseminated intravascular coagulation, cerebral or brain stem 
hemorrhage, cerebral edema and spontaneous rupture of subcapsular liver hematoma. 
Purtscher-like retinopathy can result in permanent visual loss (Stewart et al., 2007).  
Newborns from women with HELLP syndrome delivered before the 32th to 34th gestational 
week are at risk for intrauterine growth restriction, cardiovascular (i.e. persisting ductus 
arteriosus) and respiratory complications, and perinatal death due to prematurity, abruptio 
placentae or cerebral hemorrhage (i.e. caused by neonatal thrombocytopenia). Notably, 
complications in the newborn appear to be rather related to prematurity than to HELLP 
syndrome itself. 
In women developing HELLP syndrome after the 34th week of pregnancy, vaginal delivery 
is the method of choice. Before the 34th gestational week, a single course of 12 mg 
betamethasone twice, 24 hours apart, is recommended to induce lung maturation. Repeated 
glucocorticoid courses may be more effective; however, they may lead to fetal growth 
restriction and prolonged adrenal suppression. High-dose dexamethasone treatment has 
been proposed as an alternative to improve maternal outcome, especially before 27th week of 
pregnancy, but there is no evidence of benefits compared to immediate delivery and thus 
should be individually addressed (Fonseca et al., 2005; Haram et al., 2009).  
4.2.2 Lymphocytic (autoimmune) hypophysitis 
Lymphocytic hypophysitis is a rare inflammatory disorder of the pituitary gland thought to 
have an autoimmune basis with predilection for women during the postpartum period and 
the late stage of pregnancy. Although lymphocytic hypophysitis should be always 
considered in the differential diagnosis of pituitary masses and/or pituitary insufficiency in 
women who are pregnant or in the early postpartum period, a definitive diagnosis of the 
disease requires pituitary biopsy. Nevertheless, a presumptive diagnosis of lymphocytic 
(autoimmune) hypophysitis is possible based on a history of gestational or postpartum 
pituitary insufficiency, rapid development of hypopituitarism in up to 75-80% of cases with 
early loss of adrenocorticotrophic hormone (ACTH) and TSH, and imagistic appearance of 
the pituitary gland and stalk including variable enlargement of the hypophysis with 
homogenous appearance and intact sella floor. Cystic appearance of the pituitary gland on 
magnetic resonance imaging (MRI), although rare, is not excluded in patients with 
autoimmune hypophysitis (Flanagan et al., 2002). In hypophysitis, the pituitary stalk is 
thickened but not displaced, an aspect that is opposed to the MRI of the displaced 
hypophyseal stalk that is described in macroadenomas with supra-sellar enlargement. A 
strong, homogenous enhancement of the anterior pituitary after gadolinium infusion, even 
though suggests inflammation, is not specific enough to differentiate between hypophysitis 
on one hand and pituitary adenoma on the other hand.  
Autoimmune inflammation of the pituitary gland presents commonly as lymphocytic 
adenohypophysitis. The clinical presentation of autoimmune adenohypophysitis includes 
headache, pituitary insufficiency and central diabetes insipidus. Visual disturbances 
comprise visual field defects due to compression of the optic chiasm and diplopia due to 
compression of III, IV and VI cranial nerves by parasellar expansion of the autoimmune 
inflammatory process towards the cavernous sinus. Diabetes insipidus may be a component 
of pure lymphocytic adenohypophysitis because of inhibition of the axonal transport of 
www.intechopen.com
 
Diabetes Insipidus 88
AVP by swelling of the pars tuberalis of the adenophypophysis which covers the 
infundibulum anterolaterally. From the clinical viewpoint, diabetes insipidus can be masked 
by coexistence of glucocorticoid deficiency in lymphocytic adenohypophysitis which is 
associated with stimulation of ADH release and aquaporin-2 synthesis (Caturegli et al., 
2005) and is often revealed by glucocorticoid hormones replacement therapy. Long-term 
imagistic observation of few cases with a medical history of lymphocytic hypophysitis 
during pregnancy suggested that this clinical condition may evolve with pituitary atrophy 
and empty sella. Hence, it is believed that at least some cases with postpartum pituitary 
insufficiency (even Sheehan’s syndrome) and empty sella may actually include lymphocytic 
adenohypophysitis (Ishihara et al., 1996).  
Rarely, autoimmune inflammation of the pituitary gland may be limited to the posterior 
pituitary lobe and infundibular stem and termed lymphocytic infundibulo-hypophysitis. 
Lymphocytic infundibulo-hypophysitis has been reported as a cause of central diabetes 
insipidus in the postpartum period (VanHavenbergh et al., 1996). On MRI, infundibulo-
hypophysitis is suspected on enlargement of the posterior pituitary lobe and thickening of 
the pituitary stalk greater than 3 mm at the level of the median eminence of the 
hypothalamus (Caturegli et al., 2005). Although loss of physiological T1 hyper-intensity in 
the posterior pituitary is suggestive, specificity of this aspect is low.     
4.2.3 Pituitary apoplexy 
Hemorrhagic or ischemic pituitary apoplexy is a rare neuro-endocrine emergency with a 
potentially severe outcome resulting even in hyponatremic coma and death. The main 
clinical symptoms are thunderclap headache, nausea and vomiting, fever, loss of 
consciousness, ophtalmoplegia, visual field impairment, monocular blindness and neck 
stiffness (meningeal irritation). The diagnosis is most challenging in apparently healthy 
subjects (Georgescu et al., 2009) in whom neurological complications such as stroke, 
meningitis, diffuse subarachnoid hemorrhage or optic tract hemorrhage may develop. 
Occasionally, pituitary apoplexy may present as isolated unilateral or bilateral IIIrd or VIth 
nerve palsy. 
In most cases, pituitary apoplexy complicates the evolution of previously diagnosed 
adenomas. In a retrospective review of 28 cases with pituitary adenoma, 14% of patients 
were incidentally diagnosed after pituitary apoplexy (Dekkers et al., 2007) and in a follow-
up of 42 patients with incidentally found non-functioning pituitary adenoma, apoplexy 
complicated the natural course of the disease in 9.5% of cases. On the other hand, in a large 
series of 45 cases of subjects with pituitary apoplexy, only 18% were known to have 
pituitary adenoma at presentation (Sibal et al., 2004). Likewise, in a larger series of 62 
patients with this clinical condition, 81% of subjects had no previous medical history 
suggesting pituitary tumor (Semple et al., 2005).  
Pituitary apoplexy in pregnancy and postpartum is even more rarely encountered with less 
than 50 cases reported in the medical literature. Occasionally, spontaneous abortion 
develops during the follow-up (Krull et al., 2010). To confirm diagnosis, pituitary hormones 
evaluation and MRI assessment of the hypothalamus-pituitary region is mandatory. MRI is 
revealing a sellar mass with fluid level or central component suggesting hemorrhage. 
Extrasellar expansion is common resulting in pituitary stalk displacement and optic chiasm 
compression.  
Pituitary insufficiency of various degrees follows the onset of pituitary apoplexy. Note 
worthily, the association of pituitary apoplexy with permanent or transient diabetes 
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insipidus is rather rare, irrespective of gender and physiological status; in two larger 
studies, of 62 and 40 patients, respectively, only 8% of subjects developed AVP deficiency 
(Semple et al., 2005; Lubina et al., 2005). Artery surgery, other major surgery, pregnancy, 
gamma knife irradiation, anticoagulant therapy, and coagulopathy secondary to liver failure 
were identified as precipitating factors for pituitary apoplexy. Specific information on the 
prevalence of diabetes insipidus in women developing pituitary apoplexy in pregnancy and 
postpartum is not yet available.  
With except of cases developing compression of the optic chiasm or severe neurological 
status, pituitary apoplexy in pregnancy should be treated preferably conservatively with 
high-dose glucocorticoid therapy and hormone replacement therapy including AVP- or 
DDAVP medication if diabetes insipidus is diagnosed. Monitoring by MRI is recommended. 
In advanced gestation delivery is preferred.   
4.2.4 Sheehan’s syndrome 
Sheehan’s syndrome describes postpartum pituitary necrosis; however, the exact pathogenic 
mechanism of the syndrome is not well understood because such endocrine abnormalities 
are not obvious in most women with severe hemorrhage in pregnancy and delivery. 
Although not a typical feature of Sheehan’s syndrome, early postpartum diabetes insipidus 
may accompany postpartum pituitary necrosis in about 5% of cases and even more when 
systematically looked for. In a study on posterior pituitary function in 26 women with 
Sheehan’s syndrome by both water deprivation and 5% hypertonic saline infusion test, 
partial diabetes insipidus was diagnosed in 29.6% of patients (Atmaca et al., 2007). Likewise, 
plasma AVP measurements after the 5% hypertonic saline infusion test in women with 
postpartum hypopituitarism but absent polyuria revealed, in 10 of 12 patients, the presence 
of various degrees of subnormal AVP responses to the increase in plasma osmolality 
(Iwasaki et al., 1989). Higher osmotic threshold for thirst perception was described in 
Sheehan’s syndrome patients in comparison to controls; thus, besides AVP insufficiency, 
ischemic damage of the thirst center may contribute to increased osmotic threshold for the 
onset of thirst in Sheehan’s syndrome (Atmaca et al., 2007).  
Occasionally, in women with pre-pregnancy diagnosis of Sheehan’s syndrome, latent central 
diabetes insipidus may became manifest during pregnancy (Briet et al., 1998) to be corrected 
with vasopressin therapy. Water metabolism disturbances in patients with Sheehan’s 
syndrome depend on several factors such as the degree of pituitary damage, the time of 
onset since the pituitary injury, association of co-morbidities and/or concomitant 
medication. Emerging evidence shows that Sheehan’s syndrome with or without diabetes 
insipidus is increasingly reported in association with antiphospholipid syndrome (Mehdi et 
al., 2011). In addition, in advanced pregnancy, contribution of enhanced vasopressinase 
activity to disturbed water balance should be considered and is suggested by incomplete 
response of polyuria and polydipsia to vasopressin but adequate control by desmopressin. 
Exceptionally, postpartum Sheehan’s syndrome may evolve to acute renal failure.  
5. Impact of pregnancy-related diabetes insipidus on maternal and fetal 
health 
Pre-pregnancy confirmed, therapeutically controlled diabetes insipidus has normally no 
significant impact on pregnancy outcome and health status of the fetus. On the contrary, 
gestational diabetes insipidus is potentially related to a series of maternal-fetal 
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complications, of maximum severity in cases associated with HELLP syndrome and pre-
eclampsia. Maternal complications may include severe hypernatremia, eclampsia, hepatic 
insufficiency and disseminated intravascular coagulation. In several cases, premature 
delivery of the fetus avoids fetal hypoxia and intrauterine fetal death (Wiser et al., 2008).  
Generally, transient diabetes insipidus recovers about 4-6 weeks after delivery. Rarely, 
permanent central diabetes insipidus with or without definitive pituitary insufficiency of 
various degrees may occur in the mother, depending on the underlying clinical condition of 
pregnancy-related diabetes.  
Gestational diabetes insipidus may associate in utero fetal complications such as 
oligohydramnios or polyhydramnios. Rapid-onset polyhydramnios and fetal polyuria were 
recently described by Weinberg (Weinberg et al., 2010) in a singleton pregnancy developing 
transient third trimester gestational diabetes insipidus in the mother. Nevertheless, the 
mechanism of fetal polyuria remains elusive in this case. The authors’ speculated on either 
maternal over-hydration or an effect on fetal vasopressin of the increased maternal 
vasopressinase, for which transplacental passage has been described.  
6. Fetal disorders/conditions associated with disturbances in ADH 
production or activity and their repercussions on the pregnancy course 
Both AVP and oxytocin are synthesized by the hypothalamic supraoptic and 
paraventricular nuclei during the first weeks of fetal life. AVP is found in high 
concentrations in fetal plasma and neonate umbilical cord blood and thought to be 
involved in blood pressure regulation. The main stimulus of AVP release in the fetus is 
hypoxia but also hypotension, acidosis and hypercarbia may play a role. Aquaporin-2 
metabolism in the fetus and neonate is not fully understood. Researches in both preterm 
and at term infants suggested that in early postnatal life aquaporin-2 urinary levels cannot 
serve as a marker of AVP renal action and renal capacity to concentrate urine (Nyul et al., 
2002; Zelenina et al., 2006) although opposing results were reported (Iacobelli et al., 2006). 
Nevertheless, in the same studies urinary aquaporin-2 concentrations correlated 
adequately with the overall maturity of tubular renal function and decreased in 
conditions of impaired kidney activity. In the fetus and newborn, diabetes insipidus is a 
rare disorder with a complex pathogenesis (table 3).  
Most cases of central diabetes insipidus are secondary to a known etiology while defective 
AVP action is often related to a pathological condition and/or specific medication in the 
pregnant mother. 
Clinically, diabetes insipidus may be suspected in newborns presenting during the first days 
of life with polyuria and weight loss, and is confirmed by hypernatremia, high plasmatic 
osmolality and low urine osmolality and a good response to desmopressin. Nevertheless, 
diagnosis during the neonatal period may be difficult because of frequent lack of polyuria 
due to the decreased renal glomerular filtration that exists during the neonatal period. The 
increase in the glomerular filtration rate thereafter unmasks the later polyuria. Moreover, 
the low osmolarity of the breast milk may mask specific features of diabetes insipidus in 
neonates that are exclusively breastfed. The disorder may be suspected in infants with 
unexplained fever, irritability, lack of weight gain, hypernatremia. Often, the child can be 
calmed with water but not with milk. Rapid management is required to prevent potentially 
lethal complications such as intracranial bleeding and renal vein thrombosis. 
www.intechopen.com
 
New Insights into the Diagnosis and Management of Pregnancy-Related Diabetes Insipidus 91 
Central diabetes insipidus Nephrogenic diabetes insipidus 
Perinatal asphyxia Medication (in the mother) (e.g. lithium, 
angiotensin-converting enzyme inhibitors, 
angiotensin type 1 receptor blockers)  
Intracranial hemorrhage (e.g. vitamin K defi-
ciency) 
Familial or sporadic congenital 
nephrogenic diabetes insipidus 
Infection (e.g. congenital toxoplasmosis, con-
genital cytomegalovirus infection, meningitis: 
streptococcal, meningococcal, listeria menin-
gitis, brain abscess) 
 
Congenital defects in the brain/pituitary 
morphogenesis (e.g. pituitary agenesis/hypo-
genesis, septo-optic dysplasia,  holoprosence-
phaly, congenital nasal pyriform aperture 
stenosis, cleft lip/palate, meningomyelocele, 
hydrocephalus, facial diplegia (Mobius 
syndrome), Delleman syndrome, Kabuki 
syndrome etc.  
 
Cranio-cerebral trauma  
Intracranial tumors (e.g. teratoma, craniopha-
ryngioma) 
 
Cysts  
Familial central diabetes insipidus  
Wolfram syndrome*   
Table 3. Etiology and pathogenesis of diabetes insipidus in the fetus and neonate.*onset of 
diabetes insipidus is confirmed after the age of 3 month.  
6.1 Central diabetes insipidus in the fetus and neonate 
Congenital isolated central diabetes insipidus may be of idiopathic nature (Bianchi, 2010) or 
due to various underlying pathological states (Table 3). Idiopathic central diabetes insipidus 
has been particularly reported in preterm very low birth weight infants (Stapleton & Di 
Geronimo, 2000). Central diabetes insipidus appears as a component of congenital 
anomalies, in particular midline developmental defects or genetic syndromes, of which the 
most important are represented by: 
• midline craniofacial malformations (holoprosencephaly)  
• septo-optic dysplasia (De Morsier’s syndrome) is a complex disorder that consists in 
incomplete development of midline cranial structures such as hypoplasia/aplasia of the 
optic nerves, hypoplasia/absence of the septum pellucidum and/or pituitary 
hypoplasia/aplasia, with isolated or combined pituitary hormone deficiencies 
including AVP deficiency and in particular growth hormone deficiency. HESX1 gene 
mutations have been associated with septo-optic dysplasia. 
• Delleman syndrome associating somatic changes such as macrocephaly, micrognathia, 
anophtalmia, cleft lip and palate, cutis aplasia, diabetes insipidus and 
panhypopituitarism (Leichtman et al., 1994) 
• Kabuki syndrome, a multiple malformation disorder caused by mutations in the MLL2 
gene (Ng et al., 2010), a histone methyltransferase ubiquitary expressed among adult 
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human tissues; affected individuals may present with strabismus, long palpebral 
fissures, large ears, cardiac and immunological anomalies, dwarfism and mental 
retardation. Diabetes insipidus may develop. 
In fact, any severe defect of brain development can be associated to diabetes insipidus due 
to alterations in pituitary embryogenesis.  
• Pituitary agenesis/hypogenesis with absence of the pituitary stalk 
• Wolfram syndrome or DIDMOAD with an autosomal recessive transmission pattern,  
which combines diabetes insipidus, diabetes mellitus, optic atrophy, deafness, atonia of 
the bladder, hydronephrosis, neurological and gastrointestinal anomalies, 
hypogonadotropic hypogonadism and depression. In contrast to diabetes mellitus 
which develops early, even during neonatal life, diabetes insipidus appears in up to 
75% of affected individuals, with a peak incidence at age 15 (range 3 months - 40 years). 
Desmopressin treatment adequately controls diabetes insipidus. The gene involved in 
most Wolfram syndrome cases is called WFS1 and located in the chromosomal region 
4p16.1. The WFS1 protein, also known as wolframin, appears to be involved in cell cycle 
regulation and apoptosis. Recently, another mutation associated with the WSF2 locus 
on chromosome 4 has been identified in patients suffering from Wolfram syndrome 
(Amr et al., 2010).  
• Familial central diabetes insipidus may be transmitted autosomal dominant, autosomal 
recessive or X-linked with variable penetrability. 
Congenital toxoplasmosis may result in central diabetes insipidus. In that case, the serum 
and cerebrospinal fluid samples of the patient test positive for toxoplasmosis. Alternatively, 
etiology is suggested by cranial computed tomography revealing obstructive hydrocephalus 
and cranial disseminated calcifications. Anterior pituitary insufficiency is occasionally cited 
in neonates with congenital toxoplasmosis with central adrenal insufficiency and central 
hypothyroidism (Siahanidou et al., 2006). One case of prolonged fever, attributed to 
hypothalamic dysfunction (hypothalamic fever) has been reported in association to diabetes 
insipidus in a newborn diagnosed with congenital toxoplasmosis (Siahanidou et al., 2006). 
Tumors of the hypothalamus-pituitary region may account for onset of central fetal/neona-
tal diabetes insipidus. Neonatal craniopharyngioma has been repeatedly reported as a 
suprasellar tumor with partially cystic appearance in MRI and variable outcome after 
radical neurosurgery (Müller et al., 2000). Arachnoid cysts with suprasellar localization may 
manifest with pituitary insufficiency and central diabetes insipidus when the cyst reaches a 
sufficient size. In Langerhans cell histiocytosis early infiltration of the hypothalamus and 
pituitary stalk causes central diabetes insipidus. Combined Langerhans cell histiocytosis and 
DiGeorge Syndrome displaying multisystemic involvement of Letterer-Siewe disease at 
birth has been reported (Levendoglu et al., 1996). Transiently, central diabetes insipidus in 
the neonate is described in association with hypotonia, dysmorphism and marked speech 
delay due to 22q13 deletion syndrome (Barakat et al., 2004).  
6.2 Nephrogenic diabetes insipidus in the fetus and neonate 
Congenital nephrogenic either sporadic or familial diabetes insipidus is caused in 90% of 
cases by X-linked transmitted mutations in the AVP receptor 2 gene that encodes for the 
AVP type 2 receptor. Until now, five types of molecular defects in the protein synthesis or 
action have been described. The other 10% of cases result from mutations in the aquaporin-2 
gene. Autosomal recessive inheritance of the mutation results in proteins that remain 
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trapped in the endoplasmic reticulum and are rapidly degraded, whereas autosomal 
dominant inheritance results in synthesis of structurally normal proteins but inable to 
ensure intracellular transport within the tubular renal cell. In few cases of congenital 
nephrogenic diabetes insipidus neither the AVP gene nor the aquaporin-2 gene are affected.  
Note worthily, nephrogenic diabetes insipidus in the fetus may be a result of maternal 
medication such as lithium, angiotensin-converting enzyme inhibitors or angiotensin type 1 
receptor blockers. Lithium is commonly used in the treatment of psychiatric disorders, 
specifically bipolar depression. Lithium causes polyhydramnios from fetal diabetes 
insipidus in utero. Clinical presentation of infants with in utero lithium exposure comprises 
transient neuro-developmental deficiencies such as hypoglycemia, hyperbilirubinemia, 
hypotonia, respiratory distress syndrome, cyanosis, lethargy, and weak suck and Moro 
reflexes in the neonatal period. Additionally, large-for-gestational age and prematurity, 
Ebstein’s anomaly, cardiovascular toxicity and endocrine complications have been reported. 
Of endocrine disorders, newborns are at risk to develop nephrogenic diabetes insipidus and 
thyroid dysfunction (Kozma et al., 2005).  
Alternatively, other congenital tubulopathies can associate a partial defect in the capacity to 
concentrate urine and usually present with a low degree of polyuria (e.g. Bartter syndrome, 
Fanconi syndrome, nephronophtisis, polycystic kidneys, obstructive nephropathy, nephritis, 
renal insufficiency).  
7. Diagnostic challenges in pregnancy-related diabetes insipidus 
Whatever etiology of diabetes insipidus, the main feature consists of excretion of high 
amounts of dilute, flavorless, hypotonic urine. Irrespective of the pathogenesis of the 
disorder (i.e. central, gestational or nephrogenic diabetes insipidus), a primary deficiency in 
urinary concentration will result in a rise of urine flow that produces a slight (1% to 2%) 
decrease in body water and a commensurate rise in basal plasma osmolality and sodium. 
Therefore, high urine output with low urine specific gravity (<1005) and low urine 
osmolality (50-300 mOsm/kg) in the presence of normal or elevated sodium (148 mmol/l) 
or plasma osmolality strongly suggests diabetes insipidus. Exclusion of other causes of 
polyuria such as diabetes mellitus, renal failure, hypokalemia, hypercalcemia and tubular 
renal acidosis is made by determination of fasting glucose and oral glucose tolerance test, 
urea, creatinine, creatinine clearance and electrolytes in blood and urine. Adrenal function 
tests, thyroid tests and basal and dynamic tests of pituitary function should be considered. 
The practice of relating plasma to urine osmolality is useful; it can quickly differentiate 
diabetes insipidus from parenteral fluid excess. The urine osmolality is a measure of the 
concentration of the urine and is determined by AVP concentration. In a hypernatremic 
patient, a urine osmolality below that of the plasma suggests diabetes insipidus.  
In contrast to women with primary polyuria, women with diabetes insipidus will not 
concentrate their urine osmolality during the water deprivation test. However, differential 
diagnosis from primary polydipsia may be difficult in women with partial AVP deficiency 
since fluid restriction can increase AVP secretion sufficiently to concentrate the urine. 
Additionally, the water deprivation test performed during pregnancy needs closed 
observation of the patient and may be problematic because the resulting plasma volume 
may lead to important dehydration and may increase the risk of utero-placental 
insufficiency. In this case diagnostic tests may be limited to measurement of urine and 
plasma osmolality and AVP or DDAVP administration.  
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Partial or mild forms of diabetes insipidus, however, cannot be clearly differentiated by 
indirect tests. In these cases, plasma AVP measurement with a high sensitivity assay, before 
and after water deprivation or osmotic stimulation during infusion of hypertonic 5% saline 
increases diagnosis accuracy (Zerbe & Robertson, 1981). Using a nomogram, AVP remains low 
after hypertonic saline infusion in patients with cranial diabetes insipidus while it increases 
normally in relation to plasma osmolality in patients with primary polyuria. Pregnant women 
with pre-existing central diabetes insipidus will respond by increased urine osmolality after 
intranasal delivery of AVP or AVP injection, as will patients developing hypothalamus-
pituitary disorders during pregnancy. In contrast, vasopressin resistance is well-described in 
transient or recurrent gestational diabetes insipidus due to vasopressinase, however, patients 
will adequately respond to DDAVP. If there is a normal response to AVP or DDAVP that is 
urine osmolality obtained 30–60 min after injection increases, nephrogenic diabetes insipidus 
can be ruled out. All pregnant women with diabetes insipidus of unclear etiology should 
undergo magnetic resonance imaging of the hypothalamus-pituitary region to establish 
coexistence of disorders that may have affected AVP-producing neurons.  
Notably, differential diagnosis of diabetes insipidus in pregnant women without pre-dating 
disease may be challenging and, occasionally, certainty with regard to the etiopathogeny is 
obtained after delivery. However, it has to be kept in mind that persistence of polyuria and 
polydipsia more than 6 weeks postpartum questions the diagnosis of true gestational 
diabetes insipidus and needs re-evaluation of the case. 
8. Therapy of diabetes insipidus in pregnancy and lactation 
Once the diagnosis is established, close monitoring of vital signs, fetal status, fluid balance, 
body weight and renal function are essential. Fluid intake must approximate urine volume 
and other fluid losses. Many patients require parenteral treatment, which usually consists of 
5% glucose and normal saline infusion. Vaginal delivery with regional analgesia or, in the 
case of cesarean section, spinal anesthesia, are the methods of choice. 
Earlier pituitary extracts of AVP contained oxytocin and precipitated uterine contractions 
and preterm labor. Chlorpropamide can stimulate secretion of AVP and potentiate its effects 
but it can cause fetal hypoglycemia and neonatal diabetes insipidus.  
Because AVP degradation by vasopressinase is initiated by clipping the first amino-acid of 
the hormone, whereas its analog called DDAVP (1-deamino-8-D-arginine vasopressin, 
desmopressin acetate) is devoid of the first amino acid of AVP, the treatment of choice in 
patients with pregnancy-related diabetes insipidus is DDAVP. In contrast to the naturally 
occurring hormone, arginine-vasopressin, DDAVP exhibits practically no pressor activity 
and a prolonged antidiuretic activity lasting from 8 to 12 h (Fjellestad-Paulsen et al., 1993). 
There are several routes of administration of DDAVP. In pregnancy, the intranasal, oral or 
sublingual routes are preferred (Table 4).  
 
Intransal Oral Sublingual (Melt) 
Spray Drops Tablets Tablets 
- 5 µg 100 µg 60 µg 
10 µg 10 µg 200 µg 120 µg 
20 µg 20 µg 400 µg 240 µg 
Table 4. Dose comparison of different DDAVP (desmopressin acetate) formulations. 
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Decreased response to nasal DDAVP may occur during episodes of rhinitis. In these cases or 
when oral administration is not possible, and in the postoperative period, the parenteral 
form (4 µg/ml, intravenously, intramuscularly or subcutaneously) is preferred.  
Experience with the use of DDAVP during pregnancy is increasing; it is safe for both the 
mother and the fetus. In fact, DDAVP appears not to cross the placenta within detectable 
limits (Ray et al., 2004). To be mentioned, however, there is large individual variation in the 
amplitude and duration of effect. Hence, doses have to be tailored individually for optimal 
efficacy.  
Hyponatremia is reported to occur after first doses of DDAVP in patients who do not 
restricte oral water intake; therefore, desmopressin carries the potential hazard of dilutional 
hyponatremia if the patient continues to drink inappropriately despite persistent 
antidiuresis. Lower extremity edema and signs of water intoxication may develop in cases 
with excessive dosage.  
9. Conclusion  
Diabetes insipidus in pregnancy and postpartum is an endocrine disorder with potentially 
serious consequences on the maternal course of gestation and on fetal development and 
health when occurring in association with life-threatening clinical conditions such as 
preeclampsia, HELLP syndrome or pituitary insufficiency. Although described more than 
one hundred years ago, the disease is not fully understood from the pathophysiological 
point of view and appears to be under-diagnosed. Basically, most information available in 
this area of knowledge resulted from isolated case reports or case series reviews, while on 
the contrary few conclusions were drawn from systematic studies documenting disease 
prevalence and therapy. To improve knowledge in the diagnosis and multispecialty 
management of women with pregnancy-related diabetes insipidus and their offspring, 
further studies are warranted. 
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